Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Neptuniplan Maritime in financing of ANCS acquisition
Mandate

Vinge advises Neptuniplan Maritime in financing of ANCS acquisition

August 25, 2025

Vinge has advised Neptuniplan Maritime Holding AB in connection with entering into a more than EUR 133 000 000 facilities agreement with Citibank, Danske Bank and Nordea for the purpose of, among other things, financing its acquisition of Wärtsilä’s Automation, Navigation and Control Systems (ANCS) business. Operations will be continuing under NACOS Marine, who provides, among other things, advanced solutions in vessel navigation, automation, and control systems, as well as adaptive autopilots and Guidance Marine, a leader in position reference sensor technology for dynamic positioning and maritime safety.

Neptuniplan Maritime Holding AB is a portfolio company owned by the Swedish investment firm Solix Group AB.

Vinge’s team consisted of Henrik Ossborn, Jolinn Uhlin and William Carlberg Johansson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025